UCB (STU:UNC) Other Stockholders Equity: €-37 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:UNC UCB SA STU:UNC
91 GF Score
Price €235.90
GF Value €211.55
Valuation Modestly Overvalued
View Full Analysis

What is UCB Other Stockholders Equity?

UCB STU:UNC +1.90% 91 Other Stockholders Equity is €-37 Mil as of Dec. 2025. GuruFocus rates STU:UNC with a GF Score™ of 91/100 and a GF Value™ of €211.55 (Modestly Overvalued).

UCB's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €-37 Mil.

UCB's quarterly Other Stockholders Equity declined from Dec. 2024 (€404 Mil) to Jun. 2025 (€-51 Mil) but then increased from Jun. 2025 (€-51 Mil) to Dec. 2025 (€-37 Mil).

UCB's annual Other Stockholders Equity increased from Dec. 2023 (€136 Mil) to Dec. 2024 (€404 Mil) but then declined from Dec. 2024 (€404 Mil) to Dec. 2025 (€-37 Mil).

UCB Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for UCB's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Other Stockholders Equity Chart

UCB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -127.00 368.00 136.00 404.00 -37.00

UCB Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 136.00 256.00 404.00 -51.00 -37.00
STU:UNC
91GF Score
UCB SA STU:UNC
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UCB Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-37 Mil mean?
UCB (STU:UNC) has a Other Stockholders Equity of €-37 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on UCB and its competitors.
Is UCB's Other Stockholders Equity too high?
UCB's current Other Stockholders Equity is €-37 Mil. Overall, UCB has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Other Stockholders Equity compare to VRTX and REGN?
UCB's Other Stockholders Equity of €-37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on UCB and its competitors. UCB's current Other Stockholders Equity is €-37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Overvalued. The stock's GF Value™ is €211.55, compared to a current price of €235.90 — trading 11.5% above its estimated fair value. The current Other Stockholders Equity is €-37 Mil. UCB's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For UCB (STU:UNC), the current Other Stockholders Equity is €-37 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of €235.90 is trading 11.5% above its estimated GF Value™ of €211.55. GuruFocus considers UCB to be Modestly Overvalued.

Key valuation signals for STU:UNC:

  • Other Stockholders Equity: €-37 Mil
  • GF Value™: €211.55 vs. price of €235.90 (11.5% above fair value)
  • GF Score™: 91/100

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
91GF Score

Get the complete analysis for STU:UNC

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€235.90
Price
€211.55
GF Value